Search

Your search keyword '"Walldius, Göran"' showing total 200 results

Search Constraints

Start Over You searched for: Author "Walldius, Göran" Remove constraint Author: "Walldius, Göran"
200 results on '"Walldius, Göran"'

Search Results

151. Effect of chlorophenoxyisobutyric acid (CPIB) on fat-mobilizing lipolysis and cyclic AMP levels in rat epididymal fat

152. Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol quantitative regression Swedish trial (PQRST): A status report

156. Improved prediction of 10‐year risk of severe liver disease in the general population using commonly available biomarkers.

157. Lipid levels in midlife and risk of atrial fibrillation over 3 decades—Experience from the Swedish AMORIS cohort: A cohort study.

158. Alterations in Biomarkers Related to Glycemia, Lipid Metabolism, and Inflammation up to 20 Years Before Diagnosis of Type 1 Diabetes in Adults: Findings From the AMORIS Cohort.

159. The association of apolipoproteins with later-life all-cause and cardiovascular mortality: a population-based study stratified by age.

160. Impaired fasting glucose: a risk factor for atrial fibrillation and heart failure.

161. Elevated Apolipoprotein B/A-1 Ratio is Associated With an Increased Risk of Aortic Stenosis: Experience From the AMORIS Cohort.

162. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease.

163. Peripheral immune biomarkers and neurodegenerative diseases: A prospective cohort study with 20 years of follow-up.

164. Metabolic profiles to predict long-term cancer and mortality: the use of latent class analysis.

165. Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival?

166. Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort.

167. Association between serum calcium concentration and risk of incident and fatal cardiovascular disease in the prospective AMORIS study.

168. Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients.

169. Prostate cancer risk in the Swedish AMORIS study.

170. Lipoprotein components and risk of congestive heart failure in 84 740 men and women in the Apolipoprotein MOrtality RISk study (AMORIS).

171. The new oral immunomodulating drug DiNAC induces brachial artery vasodilatation at rest and during hyperemia in hypercholesterolemic subjects, likely by a nitric oxide-dependent mechanism

173. O-0019SERUM CALCIUM AND RISK OF GASTROINTESTINAL CANCER.

174. Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio-Experience from the Swedish AMORIS cohort: A cohort study.

175. A Swedish primary healthcare prevention programme focusing on promotion of physical activity and a healthy lifestyle reduced cardiovascular events and mortality: 22-year follow-up of 5761 study participants and a reference group.

176. Association of Serum Immunoglobulin Levels with Solid Cancer: A Systematic Review and Meta-analysis.

177. Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease.

178. Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort.

179. Lipids, Apolipoproteins, and the Risk of Parkinson Disease.

180. Baseline serum folate, vitamin B12 and the risk of prostate and breast cancer using data from the Swedish AMORIS cohort.

181. Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study.

182. The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: A study in the Swedish AMORIS cohort.

183. Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study.

184. Iron metabolism and risk of cancer in the Swedish AMORIS study.

185. Serum calcium and incident and fatal prostate cancer in the Swedish AMORIS study.

186. The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study.

187. Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study.

188. Gamma-glutamyl transferase and C-reactive protein as alternative markers of metabolic abnormalities and their associated comorbidites: a prospective cohort study.

189. Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation.

190. Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer.

191. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study.

193. Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study.

194. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population.

195. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects.

196. [Apolipoproteins are better risk markers than conventional lipids].

199. [Apolipoproteins are new and better risk indicators of myocardial infarction].

200. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.

Catalog

Books, media, physical & digital resources